Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Exelixis, Inc.
The operating environment for medical technology companies becomes more complex, competitive and costly every year. There is no expectation that 2022 will buck that trend, even as the medtech sector prepares for a third year of working under conditions shaped by the COVID-19 pandemic.
Jeannette Bankes, the general manager of Alcon’s global surgical business, talked to Medtech Insight about how the company is addressing the cataract surgery market with a range of intraocular lenses intended to return the patients vision to as close to its natural optimal function as possible.
Moderna co-founder Robert Langer shared tips to drive innovation at a recent summit, while narrating a fascinating tale of tenacity during the development of angiogenesis inhibitors with Judah Folkman. If an idea is important, it’s sure to be criticized, said the man who has over 1,000 patents issued or pending worldwide.
Ivantis markets the Hydrus Microstent for minimally invasive glaucoma surgery, a field Alcon exited three years ago when it pulled its CyPass from the market
- Other Names / Subsidiaries
- X-Ceptor Therapeutics, Inc.